Showing results (31-40 of 584) with videos related to
Sort By:
Pageof 59
Future Oncology (London, England)|November 16, 2017
Durvalumab in non-small-cell lung cancer patients: current developmentsLaura Mezquita, David PlanchardTherapeutic Advances in Medical Oncology|January 12, 2016
ALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsIvana Sullivan, David PlanchardFuture Oncology (London, England)|October 10, 2015
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patientsJordi Remon, David PlanchardBulletin Du Cancer|March 28, 2025
[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression]Antoine Lefèvre, Benjamin BesseCurrent Opinion in Oncology|January 7, 2017
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancerJordi Remon, Benjamin BesseESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin BesseTranslational Lung Cancer Research|July 23, 2021
Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative reviewCharles Naltet, Benjamin BesseFrontiers in Oncology|April 27, 2018
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and TreatmentJ Remon, Benjamin BesseBulletin Du Cancer|September 13, 2007
[Gemcitabine and non small-cell lung cancer]Stéphane Vignot, Benjamin BessePageof 59